Re: Singh et  al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: result of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785)

We read the article published by Singh et  al1 with great interest. However, we believe that some discussion is required. The authors present results of 2 studies assessing clinical benefits of nepafenac 0.3% over vehicle in reducing the risk of pseudophakic cystoid macular edema (PCME) in phacoemulsification cataract surgery.
Source: Ophthalmology - Category: Opthalmology Authors: Tags: Correspondence Source Type: research